The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global CNS Therapeutics Market Research Report 2024

Global CNS Therapeutics Market Research Report 2024

Publishing Date : Jun, 2023

License Type :
 

Report Code : 1781424

No of Pages : 104

Ask Your Query

Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson’s disease, dystonia, and essential tremor are central nervous system conditions. What they have in common is the loss of sufficient, intact nervous system circuits that orchestrate functions as varied as memory formation (in Alzheimer’s) or voluntary motion (in movement disorders).

Global CNS Therapeutics market is projected to reach US$ 106190 million in 2029, increasing from US$ 76300 million in 2022, with the CAGR of 4.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole CNS Therapeutics market research.

Mental health segment accounted for the largest market share in 2016. It is expected to retain its dominance over the forecast period owing to developing therapeutic options for mental diseases such as personality disorders and binge eating disorders. This segment is followed by degenerative disorders segment. There is growing awareness regarding neurodegenerative diseases owing to increase in initiatives by government and nongovernment organizations, such as Alzheimer’s and Related Disorders Society of India. These organizations conduct awareness campaigns and conferences, such as Asia Pacific Conference of ADI at New Delhi and Kerala State Initiative on Dementia, which encourage the adoption of treatment for degenerative and mental disorders.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global CNS Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  •     Pfizer
  •     Janssen Pharmaceuticals
  •     Allergan
  •     Lundbeck
  •     Teva
  •     Camber Pharmaceuticals
  •     Zhejiang Haisen Pharmaceutical
  •     Jewim Pharmaceutical
  •     Cipla
  •     Merck Sharp & Dohme Corp.
  •     Eli Lilly
  •     GlaxoSmithKline
  •     Novartis
  •     LUPIN
  •     ZYDUS PHARMS
  •     Biogen
  •     Otsuka Pharmaceutical
  •     Astra Zeneca
  •     Takeda

Segment by Type

  •     Neurodegenerative Diseases
  •     Mood Disorders
  •     Schizophrenia
  •     Autism
  •     Depression

Segment by Application

  •     Hospital Use
  •     Clinic Use
  •     Household
  •     Other

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

The CNS Therapeutics report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

 1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global CNS Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
        1.2.2 Neurodegenerative Diseases
        1.2.3 Mood Disorders
        1.2.4 Schizophrenia
        1.2.5 Autism
        1.2.6 Depression
    1.3 Market by Application
        1.3.1 Global CNS Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029
        1.3.2 Hospital Use
        1.3.3 Clinic Use
        1.3.4 Household
        1.3.5 Other
    1.4 Study Objectives
    1.5 Years Considered
    1.6 Years Considered

 2 Global Growth Trends
    2.1 Global CNS Therapeutics Market Perspective (2018-2029)
    2.2 CNS Therapeutics Growth Trends by Region
        2.2.1 Global CNS Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
        2.2.2 CNS Therapeutics Historic Market Size by Region (2018-2023)
        2.2.3 CNS Therapeutics Forecasted Market Size by Region (2024-2029)
    2.3 CNS Therapeutics Market Dynamics
        2.3.1 CNS Therapeutics Industry Trends
        2.3.2 CNS Therapeutics Market Drivers
        2.3.3 CNS Therapeutics Market Challenges
        2.3.4 CNS Therapeutics Market Restraints

 3 Competition Landscape by Key Players
    3.1 Global Top CNS Therapeutics Players by Revenue
        3.1.1 Global Top CNS Therapeutics Players by Revenue (2018-2023)
        3.1.2 Global CNS Therapeutics Revenue Market Share by Players (2018-2023)
    3.2 Global CNS Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by CNS Therapeutics Revenue
    3.4 Global CNS Therapeutics Market Concentration Ratio
        3.4.1 Global CNS Therapeutics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by CNS Therapeutics Revenue in 2022
    3.5 CNS Therapeutics Key Players Head office and Area Served
    3.6 Key Players CNS Therapeutics Product Solution and Service
    3.7 Date of Enter into CNS Therapeutics Market
    3.8 Mergers & Acquisitions, Expansion Plans

 4 CNS Therapeutics Breakdown Data by Type
    4.1 Global CNS Therapeutics Historic Market Size by Type (2018-2023)
    4.2 Global CNS Therapeutics Forecasted Market Size by Type (2024-2029)

 5 CNS Therapeutics Breakdown Data by Application
    5.1 Global CNS Therapeutics Historic Market Size by Application (2018-2023)
    5.2 Global CNS Therapeutics Forecasted Market Size by Application (2024-2029)

 6 North America
    6.1 North America CNS Therapeutics Market Size (2018-2029)
    6.2 North America CNS Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
    6.3 North America CNS Therapeutics Market Size by Country (2018-2023)
    6.4 North America CNS Therapeutics Market Size by Country (2024-2029)
    6.5 United States
    6.6 Canada

 7 Europe
    7.1 Europe CNS Therapeutics Market Size (2018-2029)
    7.2 Europe CNS Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
    7.3 Europe CNS Therapeutics Market Size by Country (2018-2023)
    7.4 Europe CNS Therapeutics Market Size by Country (2024-2029)
    7.5 Germany
    7.6 France
    7.7 U.K.
    7.8 Italy
    7.9 Russia
    7.10 Nordic Countries

 8 Asia-Pacific
    8.1 Asia-Pacific CNS Therapeutics Market Size (2018-2029)
    8.2 Asia-Pacific CNS Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
    8.3 Asia-Pacific CNS Therapeutics Market Size by Region (2018-2023)
    8.4 Asia-Pacific CNS Therapeutics Market Size by Region (2024-2029)
    8.5 China
    8.6 Japan
    8.7 South Korea
    8.8 Southeast Asia
    8.9 India
    8.10 Australia

 9 Latin America
    9.1 Latin America CNS Therapeutics Market Size (2018-2029)
    9.2 Latin America CNS Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
    9.3 Latin America CNS Therapeutics Market Size by Country (2018-2023)
    9.4 Latin America CNS Therapeutics Market Size by Country (2024-2029)
    9.5 Mexico
    9.6 Brazil

 10 Middle East & Africa
    10.1 Middle East & Africa CNS Therapeutics Market Size (2018-2029)
    10.2 Middle East & Africa CNS Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
    10.3 Middle East & Africa CNS Therapeutics Market Size by Country (2018-2023)
    10.4 Middle East & Africa CNS Therapeutics Market Size by Country (2024-2029)
    10.5 Turkey
    10.6 Saudi Arabia
    10.7 UAE

 11 Key Players Profiles
    11.1 Pfizer
        11.1.1 Pfizer Company Detail
        11.1.2 Pfizer Business Overview
        11.1.3 Pfizer CNS Therapeutics Introduction
        11.1.4 Pfizer Revenue in CNS Therapeutics Business (2018-2023)
        11.1.5 Pfizer Recent Development
    11.2 Janssen Pharmaceuticals
        11.2.1 Janssen Pharmaceuticals Company Detail
        11.2.2 Janssen Pharmaceuticals Business Overview
        11.2.3 Janssen Pharmaceuticals CNS Therapeutics Introduction
        11.2.4 Janssen Pharmaceuticals Revenue in CNS Therapeutics Business (2018-2023)
        11.2.5 Janssen Pharmaceuticals Recent Development
    11.3 Allergan
        11.3.1 Allergan Company Detail
        11.3.2 Allergan Business Overview
        11.3.3 Allergan CNS Therapeutics Introduction
        11.3.4 Allergan Revenue in CNS Therapeutics Business (2018-2023)
        11.3.5 Allergan Recent Development
    11.4 Lundbeck
        11.4.1 Lundbeck Company Detail
        11.4.2 Lundbeck Business Overview
        11.4.3 Lundbeck CNS Therapeutics Introduction
        11.4.4 Lundbeck Revenue in CNS Therapeutics Business (2018-2023)
        11.4.5 Lundbeck Recent Development
    11.5 Teva
        11.5.1 Teva Company Detail
        11.5.2 Teva Business Overview
        11.5.3 Teva CNS Therapeutics Introduction
        11.5.4 Teva Revenue in CNS Therapeutics Business (2018-2023)
        11.5.5 Teva Recent Development
    11.6 Camber Pharmaceuticals
        11.6.1 Camber Pharmaceuticals Company Detail
        11.6.2 Camber Pharmaceuticals Business Overview
        11.6.3 Camber Pharmaceuticals CNS Therapeutics Introduction
        11.6.4 Camber Pharmaceuticals Revenue in CNS Therapeutics Business (2018-2023)
        11.6.5 Camber Pharmaceuticals Recent Development
    11.7 Zhejiang Haisen Pharmaceutical
        11.7.1 Zhejiang Haisen Pharmaceutical Company Detail
        11.7.2 Zhejiang Haisen Pharmaceutical Business Overview
        11.7.3 Zhejiang Haisen Pharmaceutical CNS Therapeutics Introduction
        11.7.4 Zhejiang Haisen Pharmaceutical Revenue in CNS Therapeutics Business (2018-2023)
        11.7.5 Zhejiang Haisen Pharmaceutical Recent Development
    11.8 Jewim Pharmaceutical
        11.8.1 Jewim Pharmaceutical Company Detail
        11.8.2 Jewim Pharmaceutical Business Overview
        11.8.3 Jewim Pharmaceutical CNS Therapeutics Introduction
        11.8.4 Jewim Pharmaceutical Revenue in CNS Therapeutics Business (2018-2023)
        11.8.5 Jewim Pharmaceutical Recent Development
    11.9 Cipla
        11.9.1 Cipla Company Detail
        11.9.2 Cipla Business Overview
        11.9.3 Cipla CNS Therapeutics Introduction
        11.9.4 Cipla Revenue in CNS Therapeutics Business (2018-2023)
        11.9.5 Cipla Recent Development
    11.10 Merck Sharp & Dohme Corp.
        11.10.1 Merck Sharp & Dohme Corp. Company Detail
        11.10.2 Merck Sharp & Dohme Corp. Business Overview
        11.10.3 Merck Sharp & Dohme Corp. CNS Therapeutics Introduction
        11.10.4 Merck Sharp & Dohme Corp. Revenue in CNS Therapeutics Business (2018-2023)
        11.10.5 Merck Sharp & Dohme Corp. Recent Development
    11.11 Eli Lilly
        11.11.1 Eli Lilly Company Detail
        11.11.2 Eli Lilly Business Overview
        11.11.3 Eli Lilly CNS Therapeutics Introduction
        11.11.4 Eli Lilly Revenue in CNS Therapeutics Business (2018-2023)
        11.11.5 Eli Lilly Recent Development
    11.12 GlaxoSmithKline
        11.12.1 GlaxoSmithKline Company Detail
        11.12.2 GlaxoSmithKline Business Overview
        11.12.3 GlaxoSmithKline CNS Therapeutics Introduction
        11.12.4 GlaxoSmithKline Revenue in CNS Therapeutics Business (2018-2023)
        11.12.5 GlaxoSmithKline Recent Development
    11.13 Novartis
        11.13.1 Novartis Company Detail
        11.13.2 Novartis Business Overview
        11.13.3 Novartis CNS Therapeutics Introduction
        11.13.4 Novartis Revenue in CNS Therapeutics Business (2018-2023)
        11.13.5 Novartis Recent Development
    11.14 LUPIN
        11.14.1 LUPIN Company Detail
        11.14.2 LUPIN Business Overview
        11.14.3 LUPIN CNS Therapeutics Introduction
        11.14.4 LUPIN Revenue in CNS Therapeutics Business (2018-2023)
        11.14.5 LUPIN Recent Development
    11.15 ZYDUS PHARMS
        11.15.1 ZYDUS PHARMS Company Detail
        11.15.2 ZYDUS PHARMS Business Overview
        11.15.3 ZYDUS PHARMS CNS Therapeutics Introduction
        11.15.4 ZYDUS PHARMS Revenue in CNS Therapeutics Business (2018-2023)
        11.15.5 ZYDUS PHARMS Recent Development
    11.16 Biogen
        11.16.1 Biogen Company Detail
        11.16.2 Biogen Business Overview
        11.16.3 Biogen CNS Therapeutics Introduction
        11.16.4 Biogen Revenue in CNS Therapeutics Business (2018-2023)
        11.16.5 Biogen Recent Development
    11.17 Otsuka Pharmaceutical
        11.17.1 Otsuka Pharmaceutical Company Detail
        11.17.2 Otsuka Pharmaceutical Business Overview
        11.17.3 Otsuka Pharmaceutical CNS Therapeutics Introduction
        11.17.4 Otsuka Pharmaceutical Revenue in CNS Therapeutics Business (2018-2023)
        11.17.5 Otsuka Pharmaceutical Recent Development
    11.18 Astra Zeneca
        11.18.1 Astra Zeneca Company Detail
        11.18.2 Astra Zeneca Business Overview
        11.18.3 Astra Zeneca CNS Therapeutics Introduction
        11.18.4 Astra Zeneca Revenue in CNS Therapeutics Business (2018-2023)
        11.18.5 Astra Zeneca Recent Development
    11.19 Takeda
        11.19.1 Takeda Company Detail
        11.19.2 Takeda Business Overview
        11.19.3 Takeda CNS Therapeutics Introduction
        11.19.4 Takeda Revenue in CNS Therapeutics Business (2018-2023)
        11.19.5 Takeda Recent Development

 12 Analyst's Viewpoints/Conclusions

 13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock